Podcasts about zmapp

Ebola vaccine developer, Dr. Gary Kobinger, talks COVID, asymptomatic carriers and the nature of viruses. Join the DemystifyingScience mailing list: http://eepurl.com/gRUCZL Dr. Kobinger is presently focused on non-profit production of a vaccine for the present pandemic. Professionally, he is best known for his role in the development of the first ebola vaccine, and ZMAPP, a monoclonal antibody treatment against the Ebolavirus. In addition to his biotechnology background, he's got a pretty extensive teaching resume. He's a professor at the universities of Pennsylvania and Manitoba, and at the University of Laval - where he serves as the Director of Infectious Disease Research. Our conversation covers all kinds of topics upon which Dr. Kobinger is uniquely qualified to ruminate. We talk about using gene therapies to treat diseases, how to leverage biology to cure sickness, the mysterious origin of viruses on Earth, the possibility of a non-profit approach to drug development, and the phenomenon of asymptomatic carriers. Subscribe & like so we can keep bringing the best conversations!!! Audio-only version available at all usual podcast locations or here: https://anchor.fm/demystifying-science More readings from us: https://demystifyingscience.com/blog Let's talk! @DemystifySci Twitter: https://twitter.com/demystifysci Instagram: https://www.instagram.com/demystifysci Facebook: https://www.facebook.com/demystifysci ~~~~~~~~~~~~~~ Music: ~~~~~~~~~~~~~~ Shilo Delay: https://soundcloud.com/laterisgone --- Support this podcast: https://anchor.fm/demystifying-science/support

While it's not an ideal piece of legislation, the Affordable Care Act (ACA) led to growing American interest in universal and single-payer healthcare models. Rosie and BJ discuss ways to implement full government-subsidized healthcare coverage for all U.S. citizens. Other countries, both co-hosts believe, have tested universal healthcare models, and the U.S. could learn from those programs, and take what works and leave behind what failed. Resources for Saving the World

O que é o Ebola? Onde ele surgiu? Como ele atua? Existe cura? E o ZMapp? Como se prevenir? E no Brasil? Ele passa pelo ar? Vai ser o fim do mundo? Devemos nos preocupar? Lembrando que os dados utilizados foram até o dia 20/10/2014, logo, hoje os números já não devem ser exatamente os mesmos. || 26 de out. de 2014 Considere apoiar financeiramente o meu trabalho! ✌ APOIA.SE: https://apoia.se/canaldoslow ✌ PATREON: https://www.patreon.com/canaldoslow ✌ PICPAY: @estevaoslow

V dnešnom podcaste budeme hovoriť o tom, ako dopadol ZMapp, nádejný liek proti ebole, v klinických testoch a o tom, ako sa nedávno narodil geneticky modifikovaný chlapec. TémyZdroje Intro Ako dopadol ZMapp v klinických testoch? GM chlapec je na svete Fakt a fikcia Outro Amid crisis, Ebola drug narrowly missed threshold to prove effectiveness First live birth using human oocytes reconstituted by spindle nuclear transfer for mitochondrial DNA mutation causing Leigh syndrome Leigh disease 20 Of The Internet's Craziest Conspiracy Theories

BACKSTAGE IN THE GLOBAL THEATRERichard welcomes, Joel Skousen, the editor and publisher of an alternative weekly news analysis service to discuss the beheading of American journalist James Foley, Ebola, and the Ferguson riots.PART TWO - VIRTUAL CURES FOR EBOLA AND OTHER DEADLY VIRUSESRichard speaks with, Dr. Cass Ingram, an author/lecturer and researcher in the field of natural remedies to discuss the recent Ebola outbreak in Africa. What is Ebola, what causes it and can an epidemic be prevented? He'll also discuss the experimental medicine called ZMapp which has dramatically reversed the conditions of two critically ill American medical missionaries who contracted the Ebola virus, while performing humanitarian work in Liberia.  In the absence of experimental medicines and vaccines, he says there is a natural protocol that can be aggressively performed to help counteract the effects of the virus.

BACKSTAGE IN THE GLOBAL THEATRERichard welcomes, Joel Skousen,

http://www.einstein.yu.edu - Jonathan Lai, Ph.D., and colleagues have engineered the first antibodies that can potentially neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. The findings were published online January 13 in the journal Scientific Reports. Dr. Lai, associate professor of biochemistry at Albert Einstein College of Medicine, and John Dye, Ph.D., branch chief of viral immunology at USAMRIID, were co-leaders on the study.

En este episodio os explicamos cómo funcionan las vacunas que se están preparando contra el virus del Ébola. Os contamos qué es lo que el cuerpo necesita hacer para reconocer al virus y cómo las vacunas intentan que el cuerpo aprenda sin necesidad de inyectarnos el virus de verdad. También os explicamos qué es el ZMapp y otros tratamientos a base de anticuerpos. Si queréis saber más sobre virus y sobre sus complejas interacciones con sus huéspedes escuchad también los capítulos s07e22, s06e43 y s01e27. Este programa se emitió originalmente el 19 de septiembre de 2014. Podéis escuchar el resto de audios de La Brújula en su canal de iVoox y en la web de Onda Cero, ondacero.es

In his final story for 60 Minutes, Bob Simon reports on the long and complicated development of ZMapp, a promising drug to combat Ebola; Steve Kroft sits down with Bradley Cooper, the star of the Oscar-nominated film "American Sniper." Learn more about your ad choices. Visit megaphone.fm/adchoices

详细内容请关注周六微信，或登录以下网址： http://english.cri.cn/7146/2014/11/21/2582s853350.htm This is NEWS Plus Special English. I'm Mark Griffiths in Beijing. Here is the news. The number of international students studying in the United States is at a record high, with almost one-third coming from China, which ranks first in the academic year. According to a report released by the Institute of International Education in the U.S., a record number of almost 890,000 international students went to the U.S. in the 2013-2014 academic year, to pursue studies in various academic courses. That's an increase of 8 percent over the previous year. Topping the list is China, which has more than 270,000 students studying in the U.S., an increase of almost 17 percent over the previous year. China accounted for 31 percent of the total number of international students. China is followed distantly by India, with around 100,000 students, an increase of 6 percent over the previous year, reversing a three-year trend of declining numbers of Indian students at the U.S. universities. In the previous year, international students contributed some 27 billion dollars to the U.S. economy. According to the report, the U.S. hosts more of the world's 4.5 million globally mobile college and university students than any other country in the world, almost doubling the figure hosted by Britain, the second leading host country. This is NEWS Plus Special English. Britain's Old Royal Naval College has unveiled the country's first major exhibition on the life of Yan Fu, a renowned Chinese thinker, educator and translator who served as a cultural bridge between China and Britain more than 100 years ago. Yan was born in 1854 and was one of the first ever Chinese students to study in Britain. At the age of 23, he was sent to the then Royal Naval College in London to study naval expertise and went on to become one of the most influential intellectuals in modern China. The exhibition is called "Yan Fu and Chinese Imperial Students at the Royal Naval College", and it showcases a myriad of historical documents, books, artifacts and photographs, seeking to portray the life and times of this extraordinary thinker and his fellow Chinese students. After finishing his studies, Yan returned to China as an accomplished "enlightenment thinker", translating and introducing to China the "Evolution and Ethics", "The Wealth of Nations" and "The Spirit of the Laws", among many other works. Through his writings and translations, Yan presented the people of China with insights into Europe's natural, social, and political sciences as well as theories of economics and philosophy, which were much needed in China at the dawn of its turbulent journey to modernity. He is still highly regarded in China today for his pioneering role in Chinese modern history. The exhibition runs until February 1 next year. You are listening to NEWS Plus Special English. I'm Mark Griffiths in Beijing. Chinese archaeologists have discovered another important site of human activity dating back 300-to-500,000 years, roughly contemporary with the Peking Man. Dozens of stone, animal bone and horn tools have been found at a limestone quarry site in a hill in the coastal city of Dalian in northeast China. Researchers have obtained more than 1,000 important samples since the joint excavation began in August by the Chinese Academy of Sciences and the Dalian Natural History Museum. Stone tools and large herbivorous animal bones that appear to have been cut or smashed by humans show the site was an important site for early human activity. Scientists explain that deer and antelope horn tools were also used at caves in Beijing's suburbs, where the skulls of Peking Man, or Homo erectus, were found in the 1920s and 1930s. Peking Man was first believed to have lived there around 500,000 years ago. But some Chinese scientists later said they were actually 200,000 years older, probably from a mild glacial period. The new discovery is likely to be the earliest cultural ruins in northeast China, making it important for the study of human evolution and the origin of culture in the region. This is NEWS Plus Special English. U.S. researchers say they've identified "weak spots" on the surface of the deadly Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. The study provided a 3-D picture of how the ZMapp antibodies bind to the virus. Using an imaging technique called electron microscopy, the new study found that two of the ZMapp antibodies bind near the base of virus, appearing to prevent the virus from entering cells. A third antibody binds near the top of the virus, possibly acting as a beacon to call the body's immune system to the site of infection. ZMapp, developed by San Diego-based Mapp Biopharmaceutical, was used in August to treat several patients diagnosed positive with the Ebola virus. Five of the seven patients who received ZMapp survived and the treatment is expected to go into clinical trials early next year.

Thank you RxWiki - sharing the truth about Ebola: With the World Health Organization (WHO) recently naming the Ebolaoutbreak in West Africa an international public health emergency, speculation about the virus has run wild on the Internet and in other forums.   Ebola is a virus that causes Ebola virus disease, which can have a fatality rate as high as 90 percent, reports the Centers for Disease Control and Prevention (CDC). The virus's origins are unknown, but scientists have speculated that outbreaks usually begin with infected animals like monkeys. Despite numerous official statements from WHO, the CDC and other health organizations, there are many misconceptions about Ebola. The following are some of those misconceptions. Ebola Is Airborne Despite what doomsday forecasters may say, you can't get Ebola from the air — or water or food, for that matter. The only way to contract Ebola is by coming in contact with infected bodily fluids, the CDC reports. Bodily fluids that can spread the Ebola virus include blood, saliva and urine. If an object like a needle or other medical instrument has been exposed to an Ebola patient's bodily fluids, that object can also spread the virus. Even physical contact won't spread Ebola as long as the uninfected person doesn't come into contact with the infected person's bodily fluids. Recommended Ebola prevention methods are similar to those of many other viruses — wash your hands regularly and don't touch an infected person. Infected People Spray Blood The former name of Ebola virus disease was Ebola hemorrhagic fever. Hemorrhaging (veins or arteries rupturing and bleeding) evokes a nightmarish image of blood spraying from every orifice — which may be why TV and movies portray Ebola like this so often. While Ebola is certainly deadly, external bleeding only happens in some Ebola cases, according to WHO. And blood doesn't spray from infected patients' bodies. Visible Ebola symptoms include a sudden, acute fever, vomiting and diarrhea. Medical testing can reveal less visible symptoms like kidney and liver damage and a lowered white blood cell count. Bringing Infected Americans Back for Treatment Will Cause an Outbreak When a man with high fever who had recently visited West Africa stepped through the doors of Mount Sinai Hospital in New York City, fears of an Ebola outbreak in the US ran high. Mount Sinai has since announced that the man did not have Ebola, but the two American health care workers in Africa who recently returned to the US for treatment did — and their return sparked some debate about the safety of purposefully bringing the virus into the country. As of publication time, though, the American patients were alive. Ebola may not be as fatal as it once was, said Donald Allegra, MD, chair of Infection Control and Pharmacy/Therapeutics at Newton Medical Center in Newton, NJ. "It was previously thought that this disease was almost universally fatal but now with our two Americans in Atlanta doing better and only about 55 percent mortality overall, significant numbers of patients are surviving and it would be interesting to know what the factors are that are helping many patients to survive," Dr. Allegra told dailyRx News. While an outbreak could technically happen anywhere, it's less likely in the US than in developing nations like Sierra Leone and Liberia, said Dr. Daniel Bausch in an interview with Voice of America. Many of the hospitals in the heart of the Ebola outbreak area — including West African countries Guinea, Sierra Leone, Liberia and Nigeria — are stretched too thin when it comes to medical supplies, medicines and health care workers, making containment of the virus more difficult. In contrast, the man at Mount Sinai Hospital was immediately put into quarantine and under constant medical care until he was cleared. Ebola Is Curable Currently, there is no vaccination or cure for Ebola. Despite this fact, rumors and myths about Ebola cures abound. WHO lists a few practices that have been falsely labeled as cures for Ebola. These include eating raw onions, drinking condensed milk and taking antibiotics, which fight bacteria, not viruses like Ebola. One treatment, however, is showing some promise, but its effectiveness has not been confirmed. The medicine is known as ZMapp, and it is supposed to block Ebola from spreading in the body. Before the two American Ebola patients opted for the experimental treatment, the only tests researchers had conducted with it were on animals. Ebola Has Spread to the US Although CDC officials believe Ebola spreading to the US is likely in the future, they also say it will not be a large outbreak. CDC Director Tom Frieden cited airline travel as the culprit in the spread of the virus across continents. "We are all connected and inevitably there will be travelers, American citizens and others who go from [West Africa] and are here with symptoms," he told Business Insider. "But we are confident that there will not be a large Ebola outbreak in the US." However, the only American to have died from Ebola in the current outbreak so far was in West Africa at the time of his infection. Anyssa Garza,Pharm.D.   RxWiki  Director, Life Sciences Library   See omnystudio.com/listener for privacy information.

Is the U.S. really prepared if an Ebola outbreak was to occur?When the news first broke about a deadly virus in Western Africa in March, you might have paid little attention. Over the last few months, the virus has taken thousands of lives. But you still may not have felt threatened.Until now.Currently, five Ebola victims are in the United States for treatment. This may have caused you to question if you're truly safe.Who are these fateful five?The first to arrive were medical missionaries Nancy Writebol and Dr. Kent Brantly. Both had been serving in Africa and were transported back to the U.S. to seek medical treatment for Ebola. They received an experimental drug, ZMapp, and have been Ebola-free ever since.Another doctor and missionary, Dr. Rick Sacra, was flown in from Africa and taken to a Nebraska hospital. He was treated for Ebola over a three-week period.Thomas Eric Duncan, a Liberian man, began showing symptoms of Ebola after visiting his family for a couple of weeks in the U.S. He is fighting for his life in a Dallas hospital, while his family anxiously awaits the potential risk of more outbreaks between them.The most recent patient, Ashoka Mukpo, an NBC journalist, arrived this morning (October 6, 2014) from Liberia. He is also currently at a Nebraska hospital to seek medical treatment.Now that Ebola is in the U.S, you might be wondering... is this the beginning of the end?Ebola, which was previously known as Ebola hemorrhagic fever, is a serious and often fatal disease that causes fever, sore throat, muscle weakness and soreness, and internal bleeding. Symptoms usually occur between seven to 21 days after exposure.How can you differentiate flu symptoms from Ebola symptoms?There are two triggers that can help determine if you have Ebola or just the common flu. One is having direct exposure, which for the moment primarily exists in western parts of African countries. The second? Even if you haven't been in those areas, you quite possibly may have had contact with someone who has and is carrying Ebola.Which raises concern with Duncan, the patient who was visiting from Liberia. He had contact with his family members and others; up to a total of 50 people. Health officials are closely monitoring these individuals.How is Ebola spread?Even though you might have been hearing that Ebola could be airborne, it can only be spread through bodily fluids. This includes (but is not limited to) spit/saliva, urine, vomit, semen, and/or feces. This also means you would have to touch the blood or body fluids of a person who is sick or has died from Ebola and have contact with your mouth, eyes, or nose in order for you to become infected.It's important to know that Ebola can live on surfaces, but the life span is limited to a few hours. But, the blood from someone who has Ebola that has dried on blankets or towels, or the virus that is located in the body of someone infected, can live from two to seven days.Once these patients are treated, does that mean they are immune to Ebola for life?Unfortunately, there are several strains of Ebola, and even though several patients have been treated, it doesn't mean they aren't "exempt" from contracting the other strains.Is the U.S. really prepared if an Ebola outbreak was to occur?Director of the National Center for Disaster Preparedness, Dr. Irwin Redlener, joins host Melanie Cole to discuss how Ebola is spread, how you can differentiate Ebola symptoms from the flu, and if the U.S. is really prepared if an Ebola outbreak comes to fruition.

Is the U.S. really prepared if an Ebola outbreak was to occur?When the news first broke about a deadly virus in Western Africa in March, you might have paid little attention. Over the last few months, the virus has taken thousands of lives. But you still may not have felt threatened.Until now.Currently, five Ebola victims are in the United States for treatment. This may have caused you to question if you're truly safe.Who are these fateful five?The first to arrive were medical missionaries Nancy Writebol and Dr. Kent Brantly. Both had been serving in Africa and were transported back to the U.S. to seek medical treatment for Ebola. They received an experimental drug, ZMapp, and have been Ebola-free ever since.Another doctor and missionary, Dr. Rick Sacra, was flown in from Africa and taken to a Nebraska hospital. He was treated for Ebola over a three-week period.Thomas Eric Duncan, a Liberian man, began showing symptoms of Ebola after visiting his family for a couple of weeks in the U.S. He is fighting for his life in a Dallas hospital, while his family anxiously awaits the potential risk of more outbreaks between them.The most recent patient, Ashoka Mukpo, an NBC journalist, arrived this morning (October 6, 2014) from Liberia. He is also currently at a Nebraska hospital to seek medical treatment.Now that Ebola is in the U.S, you might be wondering... is this the beginning of the end?Ebola, which was previously known as Ebola hemorrhagic fever, is a serious and often fatal disease that causes fever, sore throat, muscle weakness and soreness, and internal bleeding. Symptoms usually occur between seven to 21 days after exposure.How can you differentiate flu symptoms from Ebola symptoms?There are two triggers that can help determine if you have Ebola or just the common flu. One is having direct exposure, which for the moment primarily exists in western parts of African countries. The second? Even if you haven't been in those areas, you quite possibly may have had contact with someone who has and is carrying Ebola.Which raises concern with Duncan, the patient who was visiting from Liberia. He had contact with his family members and others; up to a total of 50 people. Health officials are closely monitoring these individuals.How is Ebola spread?Even though you might have been hearing that Ebola could be airborne, it can only be spread through bodily fluids. This includes (but is not limited to) spit/saliva, urine, vomit, semen, and/or feces. This also means you would have to touch the blood or body fluids of a person who is sick or has died from Ebola and have contact with your mouth, eyes, or nose in order for you to become infected.It's important to know that Ebola can live on surfaces, but the life span is limited to a few hours. But, the blood from someone who has Ebola that has dried on blankets or towels, or the virus that is located in the body of someone infected, can live from two to seven days.Once these patients are treated, does that mean they are immune to Ebola for life?Unfortunately, there are several strains of Ebola, and even though several patients have been treated, it doesn't mean they aren't "exempt" from contracting the other strains.Is the U.S. really prepared if an Ebola outbreak was to occur?Director of the National Center for Disaster Preparedness, Dr. Irwin Redlener, joins host Melanie Cole to discuss how Ebola is spread, how you can differentiate Ebola symptoms from the flu, and if the U.S. is really prepared if an Ebola outbreak comes to fruition.

完整文稿请关注周末微信，或登录以下网址： http://english.cri.cn/7146/2014/09/05/2582s843129.htm This is NEWS Plus Special English. I'm Mike Fox in Beijing, sitting in for Mark Griffiths. Here is the news. China's biggest property developer Wanda Group and Internet giants Baidu and Tencent have unveiled a new e-commerce venture in a challenge to industry leader Alibaba ahead of its stock offering in the United States. The three companies will integrate their online and offline sales, with e-commerce services in Wanda's 107 shopping malls, as well as its hotels and resorts. The companies will invest 5 billion yuan, or more than 810 million U.S. dollars to start. The venture adds to competition for Alibaba, who's Taobao, Tmall and other platforms account for some 80 percent of Chinese online commerce. Alibaba is preparing for a U.S. initial public offering that analysts say might value it between 150 billion and 200 billion dollars. The new venture will develop services including online finance which will pose a challenge to Alibaba's popular banking service, Yu'ebao. China has the world's most populous Internet market, with more than 600 million web users. Experts estimated that online shopping might triple from 2011 levels to 400 billion dollars a year by 2015. This is NEWS Plus Special English. Tesla Motors in the United States and Chinese state-owned phone carrier have announced plans to build 400 charging stations for electric vehicles in a new bid to promote popular adoption of the technology in China. Under the plan, China Unicom provides locations and basic services for the stations in 120 Chinese cities, while Tesla operates the stations. The two companies will also build 20 "supercharger stations" in some of these cities to offer high-speed charging. Promoters of electric vehicles see China as a promising market thanks to Beijing's support for the technology to reduce smog. But the lack of charging infrastructure is seen as a major hurdle to winning general acceptance. Tesla delivered its first home-made electric sedans to Chinese customers in April and planned to invest several hundred million dollars to build a charging network in China. China has around 78,000 electric vehicles on the road, mostly public buses and taxies. You are listening to NEWS Plus Special English. I'm Mike Fox in Beijing. Google's secretive research laboratory is trying to build a fleet of drones designed to bypass earthbound traffic so packages can be delivered to people more quickly. The ambitious program escalates Google's technological arms race with rival Amazon.com, which is also experimenting self-flying vehicles to carry merchandise bought by customers from its online stores. Google calls its foray into drones "Project Wing". Although Google expects it to take several more years before its fleet of drones is fully operational, the company says test flights in Australia delivered a first aid kit, candy bars, dog treats and water to two farmers after traveling a distance of roughly one kilometer a few weeks ago. The video of the test flight can be seen on YouTube. Besides perfecting their aerial technology, Google and Amazon still need to gain government approval to fly commercial drones in many countries, including their home country, the United States. The U.S. Federal Aviation Administration currently allows hobbyists and model aircraft makers to fly drones, but commercial use is mostly banned. This is NEWS Plus Special English. With the holiday shopping season approaching, Samsung and LG unveiled small improvements to their computerized wristwatches to sway customers. Samsung's latest version can do more without a smartphone to go with it, while LG's has a round screen. Samsung's new Gear S can receive notifications directly from social networks, calendars and other apps. It can also make and receive phone calls. Samsung has also unveiled a headset called Gear Circle. Both products will be available starting in October. LG Electronics, meanwhile, unveiled a watch with a 1.3-inch circular screen, marking a departure from the rectangular design found in previous smartwatches from LG and others. Motorola is also expected to come out with a round-face smartwatch soon. You are listening to NEWS Plus Special English. I'm Mike Fox in Beijing. An experimental Ebola drug has healed all 18 monkeys infected with the deadly virus in a study. The move boosted hopes that, once more of it can be made, the treatment might help fight the outbreak raging through West Africa. The monkeys were given the drug, ZMapp, three to five days after they were infected with the virus and when most were showing symptoms. The drug also completely protected six other monkeys given a slightly different version of the virus three days after infection. These two studies are the first monkey tests ever done on ZMapp. Experts said it's not possible to estimate a window of opportunity for treating humans, but it was encouraging that the animals recovered even after advanced disease developed. ZMapp had never been tested in humans before two American aid workers who got Ebola while working in Africa were allowed to try it. The rest of the limited supply was given to five others. Ebola has killed more than 1,500 people this year and the World Health Organization says there could be as many as 20,000 cases before the outbreak is brought under control. A few days ago, it spread to a fifth African country - Senegal, where a university student who traveled there from Guinea was being treated.

Watch Video | Listen to the AudioRELATED LINKSCDC director: ‘Ebola will get worse before it gets better' American doctor speaks out about his Ebola recovery Doctors Without Borders: Ebola efforts need more people in the fieldDoctors Without Borders: Ebola efforts need more people in the field GWEN IFILL: Adding to the difficulty, a different strain of Ebola has appeared in the Democratic Republic of Congo, causing 13 deaths so far.  Here at home, the National Institutes of Health announced today it will start testing an experimental Ebola vaccine next week. For more on that development, I’m joined by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at NIH.  He will oversee those trials. Dr. Fauci, thanks for joining us again. What would trials like this look like? DR. ANTHONY FAUCI, Director, National Institute of Allergy and Infectious Diseases: Well, first of all, it’s an early phase one trial. And by phase one, we mean this is the first time this vaccine has been put in humans.  So safety is paramount, so you take a very small number of people, 20 in total, three at a time, and you use the vaccine to determine if there are untoward effects, any inflammation, any idiosyncratic or hypersensitivity reactions, pain or anything that might be a red flag about safety. And also you learn whether it induces the kind of response in a person that you would hope would be protective against Ebola infection.  The reason why we chose this vaccine is that it showed very favorable results in an animal model, a monkey model, in which it protected monkeys very well against a challenge with lethal Ebola. So this is a first, because it’s the first time this has been in a human, in now what will be a series of steps to ultimately develop it to determine if, in fact, it is effective. GWEN IFILL: This has been in development for some time.  You called this an uncontrolled outbreak in West Africa.  Dr. Tom Frieden for the CDC said it will get worse before it gets better.  Is it this West African outbreak which is moving this from development to trial? DR. ANTHONY FAUCI: We have been working on an Ebola vaccine for a number of years now.  This has been one of the priorities of the hemorrhagic fevers, of which Ebola is actually the worst of those. This is kind of the culmination of an iterative process of developing it.  It was certainly accelerated by what we’re seeing now with this extraordinary outbreak in certain West African countries.  So we were on the track of an Ebola vaccine, but we accelerated it.  We didn’t cut corners, but we really put the afterburners on to get things done much more quickly, so that we could get to the point where, next week, we will put this first time in a human, in a normal volunteer right here in our clinical center in Bethesda. GWEN IFILL: We have spent a lot of time trying to figure out ZMapp, the small dosage which has been experimented on humans in this latest outbreak. This plan that you’re talking about developing would be working with a large drug company, GlaxoSmithKline.  Does that make a difference in the timetable, how quickly we would see it come to market if it worked? DR. ANTHONY FAUCI: Gwen, it makes an extraordinary amount of difference.  It really is the game-changer in that. When you have a company like GlaxoSmithKline, who partners fully with the NIH, with our science and their capability of producing this, that’s how you get things done.  And, in fact, one of the reasons why we had not gotten the vaccine up to now or even drugs is that there was relatively little interest on the part of many pharmaceutical companies for either drugs or vaccines. And I think the extraordinary, dramatic situation which we’re going through right now is going to really get people’s attention and we will see a lot more interest in that, which I’m very pleased about because we really do need a vaccine and some therapeutics. GWEN IFILL: Because Ebola is such a dangerous virus, how do you ensure the safety not only for those taking it in the trial, but also for those handling the virus? DR. ANTHONY FAUCI: Well, that’s a good question, Gwen. And it’s important to point out there’s no chance at all of the vaccine giving Ebola to anyone, because we’re not giving them the Ebola virus.  We’re giving them a vaccine that has a very small component of the genetic material from Ebola that will make a protein that is again an important component of the virus, but not a virus that can actually replicate. So there’s no chance.  When we say safety, which is the first part of phase one, we’re not talking about safety of giving someone Ebola.  We’re talking about safety of an adverse reaction to the vaccine itself.  That’s an important difference. GWEN IFILL: If we’re talking about the possibility of 20,000 cases before this thing begins to subside, how do we know the vaccines are the right solution, or even are they the right solution? DR. ANTHONY FAUCI: Well, again a great question, because the solution, right now, is what we know can stop an outbreak, and that is the ability and the infrastructure to deliver infection control by isolation, by quarantine, by contact tracing, and by protecting the health care workers with proper personal protective equipment. The difficulty in those West African countries is, they don’t have that kind of infrastructure in place, and it’s truly a struggle to be able to do that kind of infection control.  Historically, under other circumstances, there have been now about 24 outbreaks of Ebola, usually in geographically-restricted areas, where it was much easier to contain it. You can contain it with good hospital and infection control capabilities. GWEN IFILL: Dr. Anthony Fauci at the National Institutes of Health, thank you very much. DR. ANTHONY FAUCI: You’re quite welcome. The post Ebola's spread hastens preparations for vaccine testing appeared first on PBS NewsHour.

Watch Video | Listen to the AudioRELATED LINKSCDC director: ‘Ebola will get worse before it gets better’ American doctor speaks out about his Ebola recovery Doctors Without Borders: Ebola efforts need more people in the fieldDoctors Without Borders: Ebola efforts need more people in the field GWEN IFILL: Adding to the difficulty, a different strain of Ebola has appeared in the Democratic Republic of Congo, causing 13 deaths so far.  Here at home, the National Institutes of Health announced today it will start testing an experimental Ebola vaccine next week. For more on that development, I’m joined by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at NIH.  He will oversee those trials. Dr. Fauci, thanks for joining us again. What would trials like this look like? DR. ANTHONY FAUCI, Director, National Institute of Allergy and Infectious Diseases: Well, first of all, it’s an early phase one trial. And by phase one, we mean this is the first time this vaccine has been put in humans.  So safety is paramount, so you take a very small number of people, 20 in total, three at a time, and you use the vaccine to determine if there are untoward effects, any inflammation, any idiosyncratic or hypersensitivity reactions, pain or anything that might be a red flag about safety. And also you learn whether it induces the kind of response in a person that you would hope would be protective against Ebola infection.  The reason why we chose this vaccine is that it showed very favorable results in an animal model, a monkey model, in which it protected monkeys very well against a challenge with lethal Ebola. So this is a first, because it’s the first time this has been in a human, in now what will be a series of steps to ultimately develop it to determine if, in fact, it is effective. GWEN IFILL: This has been in development for some time.  You called this an uncontrolled outbreak in West Africa.  Dr. Tom Frieden for the CDC said it will get worse before it gets better.  Is it this West African outbreak which is moving this from development to trial? DR. ANTHONY FAUCI: We have been working on an Ebola vaccine for a number of years now.  This has been one of the priorities of the hemorrhagic fevers, of which Ebola is actually the worst of those. This is kind of the culmination of an iterative process of developing it.  It was certainly accelerated by what we’re seeing now with this extraordinary outbreak in certain West African countries.  So we were on the track of an Ebola vaccine, but we accelerated it.  We didn’t cut corners, but we really put the afterburners on to get things done much more quickly, so that we could get to the point where, next week, we will put this first time in a human, in a normal volunteer right here in our clinical center in Bethesda. GWEN IFILL: We have spent a lot of time trying to figure out ZMapp, the small dosage which has been experimented on humans in this latest outbreak. This plan that you’re talking about developing would be working with a large drug company, GlaxoSmithKline.  Does that make a difference in the timetable, how quickly we would see it come to market if it worked? DR. ANTHONY FAUCI: Gwen, it makes an extraordinary amount of difference.  It really is the game-changer in that. When you have a company like GlaxoSmithKline, who partners fully with the NIH, with our science and their capability of producing this, that’s how you get things done.  And, in fact, one of the reasons why we had not gotten the vaccine up to now or even drugs is that there was relatively little interest on the part of many pharmaceutical companies for either drugs or vaccines. And I think the extraordinary, dramatic situation which we’re going through right now is going to really get people’s attention and we will see a lot more interest in that, which I’m very pleased about because we really do need a vaccine and some therapeutics. GWEN IFILL: Because Ebola is such a dangerous virus, how do you ensure the safety not only for those taking it in the trial, but also for those handling the virus? DR. ANTHONY FAUCI: Well, that’s a good question, Gwen. And it’s important to point out there’s no chance at all of the vaccine giving Ebola to anyone, because we’re not giving them the Ebola virus.  We’re giving them a vaccine that has a very small component of the genetic material from Ebola that will make a protein that is again an important component of the virus, but not a virus that can actually replicate. So there’s no chance.  When we say safety, which is the first part of phase one, we’re not talking about safety of giving someone Ebola.  We’re talking about safety of an adverse reaction to the vaccine itself.  That’s an important difference. GWEN IFILL: If we’re talking about the possibility of 20,000 cases before this thing begins to subside, how do we know the vaccines are the right solution, or even are they the right solution? DR. ANTHONY FAUCI: Well, again a great question, because the solution, right now, is what we know can stop an outbreak, and that is the ability and the infrastructure to deliver infection control by isolation, by quarantine, by contact tracing, and by protecting the health care workers with proper personal protective equipment. The difficulty in those West African countries is, they don’t have that kind of infrastructure in place, and it’s truly a struggle to be able to do that kind of infection control.  Historically, under other circumstances, there have been now about 24 outbreaks of Ebola, usually in geographically-restricted areas, where it was much easier to contain it. You can contain it with good hospital and infection control capabilities. GWEN IFILL: Dr. Anthony Fauci at the National Institutes of Health, thank you very much. DR. ANTHONY FAUCI: You’re quite welcome. The post Ebola’s spread hastens preparations for vaccine testing appeared first on PBS NewsHour.

Si quieres ayudar a Ilich Lazo Soto con sus medicamentos, lo puedes hacer visitando: http://www.youcaring.com/medical-fundraiser/save-ilich-s-life-/209998 Hay dos mil infectados con Ebola, pero como son negros, vamos a enviarle 12 dosis de la droga experimental: http://www.dailymail.co.uk/news/article-2724942/The-impossible-dilemma-Experimental-Ebola-drug-Zmapp-arrives-Africa-12-doses-fears-effects-raise-questions-treated.html http://www.lgbtqnation.com/2014/08/rick-wiles-ebola-could-solve-americas-problems-with-atheism-homosexuality Roosevelt Roads: http://www.metro.pr/economia/reciben-ocho-propuestas-de-desarrollo-para-roosevelt-roads/pGXnho!UfpgpDtB7ZMiI Asesinato en el patio de mi casa: http://www.metro.pr/mundo/identifican-en-missouri-a-policia-que-mato-a-joven/BtInhp!irpctL9ZA1Gcu10n2elEKQ http://www.usatoday.com/story/news/nation/2014/08/16/michael-brown-shooting-ferguson-missouri-police/14152447 ¿Ustedes se enteraron de esta pendejá? http://www.usatoday.com/story/sports/nascar/2014/08/15/tony-stewart-will-decide-when-he-will-race-again/14103355 El hamburger de Rand Paul: https://www.youtube.com/watch?v=7HCpkVlX5OA Participan en el podcast: @ljvillanueva, @soyelrata, @soyelcangriman y @manolomatos. Síguenos en: @poddecachete.

Discussion of the global response to the ebola epidemic, and of a bioethical approach to the use of experimental drugs.